azathioprine has been researched along with IgG4 Related Systemic Disease in 12 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Azathioprine was used as a maintenance treatment." | 2.66 | Recurrent myelitis and asymptomatic hypophysitis in IgG4-related disease: case-based review. ( Anagnostouli, M; Andreadou, E; Boutzios, G; Evangelopoulos, ME; Fragoulis, GE; Kilidireas, C; Koutsis, G; Stefanis, L; Toulas, P; Tzanetakos, D; Tzartos, J; Vakrakou, AG; Velonakis, G, 2020) |
| "Azathioprine has previously been used in systemic cases of IgG4-RD but has not been reported for isolated esophageal disease." | 1.72 | Isolated esophageal IgG4-related disease presenting with progressive dysphagia and weight loss in a middle-aged man. ( Fehily, S; Holmes, JA; Lust, M; McKelvie, P; Miller, A; Poole, H, 2022) |
| "Patients with IgG4-related disease (IgG4-RD) typically respond well to initial glucocorticoid therapy, but always relapse with tapered or maintenance dosage of steroid." | 1.56 | Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort. ( Chen, D; Gao, J; Li, ZG; Liu, Y; Shen, D; Wang, K; Wang, Y; Wang, Z; Xia, C; Yang, F; Yu, G; Zeng, Q; Zhang, S; Zhu, L, 2020) |
| "We prospectively enrolled 215 newly diagnosed patients with IgG4-RD, who were initially treated with glucocorticoid (GC) alone or in combination with immunosuppressive agents (IM), and had at least 6 months of follow up." | 1.48 | Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. ( Fei, Y; Feng, R; Lai, Y; Peng, L; Wang, L; Wang, M; Zeng, X; Zhang, F; Zhang, P; Zhang, W; Zhang, X; Zhao, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 8 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Poole, H | 1 |
| Fehily, S | 1 |
| McKelvie, P | 1 |
| Miller, A | 1 |
| Lust, M | 1 |
| Holmes, JA | 1 |
| Omar, D | 1 |
| Chen, Y | 1 |
| Cong, Y | 1 |
| Dong, L | 1 |
| Vakrakou, AG | 1 |
| Evangelopoulos, ME | 1 |
| Boutzios, G | 1 |
| Tzanetakos, D | 1 |
| Tzartos, J | 1 |
| Velonakis, G | 1 |
| Toulas, P | 1 |
| Anagnostouli, M | 1 |
| Andreadou, E | 1 |
| Koutsis, G | 1 |
| Stefanis, L | 1 |
| Fragoulis, GE | 1 |
| Kilidireas, C | 1 |
| Liu, Y | 1 |
| Zeng, Q | 1 |
| Zhu, L | 1 |
| Gao, J | 1 |
| Wang, Z | 2 |
| Yang, F | 1 |
| Wang, K | 1 |
| Chen, D | 1 |
| Xia, C | 1 |
| Zhang, S | 1 |
| Wang, Y | 1 |
| Shen, D | 1 |
| Yu, G | 1 |
| Li, ZG | 1 |
| Kastin, D | 1 |
| Siegel, M | 1 |
| Anderson, R | 1 |
| Aronsohn, A | 1 |
| Yamamoto, M | 1 |
| Noda, S | 1 |
| Honda, S | 1 |
| Hirota, Y | 1 |
| Ito, T | 1 |
| Hasegawa, H | 1 |
| Kimura, N | 1 |
| Matsuo, Y | 1 |
| Iwai, H | 1 |
| Kohsaka, H | 1 |
| Yasuda, S | 1 |
| Pastor Rueda, JM | 1 |
| Alessandro, L | 1 |
| Calandri, IL | 1 |
| Cammarota, Á | 1 |
| Fernández-Codina, A | 1 |
| Pinilla, B | 1 |
| Pinal-Fernández, I | 1 |
| López, C | 1 |
| Fraile-Rodríguez, G | 1 |
| Fonseca-Aizpuru, E | 1 |
| Carballo, I | 1 |
| Brito-Zerón, P | 1 |
| Feijóo-Massó, C | 1 |
| López-Dupla, M | 1 |
| Cid, MC | 1 |
| Martínez-Valle, F | 1 |
| Wang, L | 1 |
| Zhang, P | 1 |
| Wang, M | 1 |
| Feng, R | 1 |
| Lai, Y | 1 |
| Peng, L | 1 |
| Fei, Y | 1 |
| Zhang, X | 1 |
| Zhao, Y | 1 |
| Zeng, X | 1 |
| Zhang, F | 1 |
| Zhang, W | 1 |
| Soriano Rios, A | 1 |
| Paredes, H | 1 |
| Hernández-Calleros, J | 1 |
| Uscanga-Domínguez, L | 1 |
| Peláez-Luna, M | 1 |
| Ron, R | 1 |
| Ruz-Caracuel, I | 1 |
| García, E | 1 |
| Montes-Ramírez, ML | 1 |
2 reviews available for azathioprine and IgG4 Related Systemic Disease
| Article | Year |
|---|---|
Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis.
Topics: Antirheumatic Agents; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Gluco | 2020 |
Recurrent myelitis and asymptomatic hypophysitis in IgG4-related disease: case-based review.
Topics: Adolescent; Asymptomatic Diseases; Autoimmune Hypophysitis; Azathioprine; Cervical Vertebrae; Female | 2020 |
10 other studies available for azathioprine and IgG4 Related Systemic Disease
| Article | Year |
|---|---|
Isolated esophageal IgG4-related disease presenting with progressive dysphagia and weight loss in a middle-aged man.
Topics: Azathioprine; Deglutition Disorders; Humans; Immunoglobulin G4-Related Disease; Male; Middle Aged; W | 2022 |
Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort.
Topics: Adult; Age Factors; Azathioprine; Biomarkers; Cyclophosphamide; Drug Therapy, Combination; Female; G | 2020 |
IgG 4 Autoimmune Hepatitis Presenting as Idiopathic Hypereosinophilia Syndrome.
Topics: Azathioprine; Female; Glucocorticoids; Hepatitis, Autoimmune; Humans; Hypereosinophilic Syndrome; Im | 2021 |
B cell targeted therapy for immunoglobulin G4-related disease.
Topics: Azathioprine; Humans; Immunoglobulin G4-Related Disease; Immunosuppressive Agents; Memory B Cells; R | 2021 |
Azathioprine Monotherapy for the Cases of Immunoglobulin G4-Related Disease With Contraindications to Glucocorticoids.
Topics: Azathioprine; Contraindications; Glucocorticoids; Humans; Immunoglobulin G4-Related Disease; Immunos | 2021 |
Neurological symptoms as the initial manifestation of IgG4-related disease.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Azathioprine; Cyclophosphamide; Headache; Humans; Immuno | 2020 |
Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
Topics: Adult; Aged; Azathioprine; Biomarkers; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; | 2018 |
Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Cohort Studies; Cyclophosphamide; C | 2018 |
Retroperitoneal fibrosis. Steroid treatment response seems to depend on its association to IgG4 related disease.
Topics: Adult; Age of Onset; Aged; Autoimmune Diseases; Azathioprine; Female; Follow-Up Studies; Humans; Imm | 2019 |
IgG4-related disease in a patient with HIV infection.
Topics: Azathioprine; Dyspnea; Glucocorticoids; HIV Infections; Humans; Immunoglobulin G; Immunoglobulin G4- | 2019 |